These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28178660)

  • 41. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence.
    Hirose Y; Katayama M; Mirzoeva OK; Berger MS; Pieper RO
    Cancer Res; 2005 Jun; 65(11):4861-9. PubMed ID: 15930307
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
    Li MY; Yang P; Liu YW; Zhang CB; Wang KY; Wang YY; Yao K; Zhang W; Qiu XG; Li WB; Peng XX; Wang YZ; Jiang T
    Sci Rep; 2016 Feb; 6():21141. PubMed ID: 26879272
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.
    Hirose Y; Katayama M; Berger MS; Pieper RO
    J Neurosurg; 2004 Jun; 100(6):1060-5. PubMed ID: 15200121
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
    Hirose Y; Berger MS; Pieper RO
    Cancer Res; 2001 Aug; 61(15):5843-9. PubMed ID: 11479224
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.
    Cheng MW; Wang BC; Weng ZQ; Zhu XW
    Acta Histochem; 2012 Sep; 114(5):503-9. PubMed ID: 22000864
    [TBL] [Abstract][Full Text] [Related]  

  • 46. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
    Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Temozolomide in malignant gliomas: current use and future targets.
    Villano JL; Seery TE; Bressler LR
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):647-55. PubMed ID: 19543728
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
    Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IDH1-mutant metabolite D-2-hydroxyglutarate inhibits proliferation and sensitizes glioma to temozolomide via down-regulating ITGB4/PI3K/AKT.
    Tong S; Wu J; Song Y; Fu W; Yuan Y; Zhong P; Liu Y; Wang B
    Cell Death Discov; 2024 Jul; 10(1):317. PubMed ID: 38982076
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
    Rainov NG; Fels C; Droege JW; Schäfer C; Kramm CM; Chou TC
    Cancer Gene Ther; 2001 Sep; 8(9):662-8. PubMed ID: 11593335
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
    Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
    J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
    Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
    Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
    Lu XY; Cao K; Li QY; Yuan ZC; Lu PS
    J Int Med Res; 2012; 40(3):995-1004. PubMed ID: 22906272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells.
    Sai K; Li WY; Chen YS; Wang J; Guan S; Yang QY; Guo CC; Mou YG; Li WP; Chen ZP
    Am J Chin Med; 2014; 42(2):485-503. PubMed ID: 24707876
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells.
    Uzzaman M; Keller G; Germano IM
    J Neurosurg; 2007 Apr; 106(4):646-51. PubMed ID: 17432717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
    Hirose Y; Berger MS; Pieper RO
    Cancer Res; 2001 Mar; 61(5):1957-63. PubMed ID: 11280752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methylation associated genes contribute to the favorable prognosis of gliomas with isocitrate dehydrogenase 1 mutation.
    Liu Y; Hu H; Zhang C; Wang Z; Li M; Zhang W; Jiang T
    Am J Cancer Res; 2015; 5(9):2745-55. PubMed ID: 26609481
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair.
    Dow J; Krysztofiak A; Liu Y; Colon-Rios DA; Rogers FA; Glazer PM
    Mol Cancer Res; 2021 Dec; 19(12):2057-2067. PubMed ID: 34535560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.